Cover Image
Market Research Report

Bleeding Disorders Therapeutics Market by Type and Geography - Forecast and Analysis 2020-2024

Published by TechNavio (Infiniti Research Ltd.) Product code 915888
Published Content info 170 Pages
Delivery time: 1-2 business days
Price
Back to Top
Bleeding Disorders Therapeutics Market by Type and Geography - Forecast and Analysis 2020-2024
Published: November 6, 2019 Content info: 170 Pages
Description

About this market

Technavio's bleeding disorders therapeutics market analysis considers sales from types of bleeding disorders therapeutics such as Hemophilia A, Hemophilia B, Von Willebrand disease, and other disorders. Our report also provides a detailed analysis of the market in Asia, Europe, North America, and ROW. In 2019, the Hemophilia A segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing demand for therapeutics without human or animal proteins will play a significant role in the Hemophilia A segment to maintain its market position. Also, our global bleeding disorders therapeutics market report looks at factors such as rising initiatives to increase awareness, recent approvals, and regulatory incentives. However, high costs of treatment, difficulties associated with early treatment, and challenges related to diagnosis and management of bleeding disorders may hamper the growth of the bleeding disorders therapeutics industry over the forecast period.

Overview

Rising initiatives to increase awareness

The awareness campaigns aids in the early detection of bleeding disorders, aiding patients to start therapy in the initial stages of the disorder. Organizations such as the National Hemophilia Foundation, von Willebrand Education Network, and World Federation of Hemophilia support and are focused on raising both awareness and research funds for bleeding disorders. This increasing awareness will lead to the expansion of the global bleeding disorders therapeutics market at a CAGR of almost 7% during the forecast period.

The emergence of gene therapy

Gene therapy is one of the most advanced and extensively researched treatment methods to treat hemophilia and von Willebrand disease. This therapy delivers stable insertion and expression of a gene, whose absence is responsible for a particular bleeding disorder. Therefore, the emergence and approval of gene therapies are expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global bleeding disorders therapeutics market during the forecast period 2020-2024, view our report.

Competitive Landscape

With the presence of a few significant players, the global bleeding disorders therapeutics market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading bleeding disorders therapeutics manufacturers, that include Baxter International Inc., Bayer AG, CSL Ltd., F. Hoffmann-La Roche Ltd., Grifols SA, Novo Nordisk AS, Octapharma AG, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Co. Ltd.

Also, the bleeding disorders therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Table of Contents
Product Code: IRTNTR40056

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE ANALYSIS

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Hemophilia A - Market size and forecast 2019-2024
  • Hemophilia B - Market size and forecast 2019-2024
  • Von Willebrand disease - Market size and forecast 2019-2024
  • Other disorders - Market size and forecast 2019-2024
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • R&D of novel therapies
  • Emergence of gene therapy
  • Advent of bispecific antibodies

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Baxter International Inc.
  • Bayer AG
  • CSL Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Grifols SA
  • Novo Nordisk AS
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2019
  • Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
  • Exhibit 10: Five forces analysis 2019
  • Exhibit 11: Five forces analysis 2024
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2019
  • Exhibit 18: Late-stage pipeline
  • Exhibit 19: Type - Market share 2019-2024 (%)
  • Exhibit 20: Comparison by type
  • Exhibit 21: Hemophilia A - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 22: Hemophilia A - Year-over-year growth 2020-2024 (%)
  • Exhibit 23: Hemophilia B - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 24: Hemophilia B - Year-over-year growth 2020-2024 (%)
  • Exhibit 25: Von Willebrand disease - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 26: Von Willebrand disease - Year-over-year growth 2020-2024 (%)
  • Exhibit 27: Other disorders - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 28: Other disorders - Year-over-year growth 2020-2024 (%)
  • Exhibit 29: Market opportunity by type
  • Exhibit 30: Customer landscape
  • Exhibit 31: Market share by geography 2019-2024 (%)
  • Exhibit 32: Geographic comparison
  • Exhibit 33: North America - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 34: North America - Year-over-year growth 2020-2024 (%)
  • Exhibit 35: Top 3 countries in North America
  • Exhibit 36: Europe - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 37: Europe - Year-over-year growth 2020-2024 (%)
  • Exhibit 38: Top 3 countries in Europe
  • Exhibit 39: Asia - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 40: Asia - Year-over-year growth 2020-2024 (%)
  • Exhibit 41: Top 3 countries in Asia
  • Exhibit 42: ROW - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 43: ROW - Year-over-year growth 2020-2024 (%)
  • Exhibit 44: Top 3 countries in ROW
  • Exhibit 45: Key leading countries
  • Exhibit 46: Market opportunity
  • Exhibit 47: Impact of drivers and challenges
  • Exhibit 48: Vendor landscape
  • Exhibit 49: Landscape disruption
  • Exhibit 50: Vendors covered
  • Exhibit 51: Vendor classification
  • Exhibit 52: Market positioning of vendors
  • Exhibit 53: Baxter International Inc. - Vendor overview
  • Exhibit 54: Baxter International Inc. - Business segments
  • Exhibit 55: Baxter International Inc. - Organizational developments
  • Exhibit 56: Baxter International Inc. - Geographic focus
  • Exhibit 57: Baxter International Inc. - Segment focus
  • Exhibit 58: Baxter International Inc. - Key offerings
  • Exhibit 59: Baxter International Inc. - Key customers
  • Exhibit 60: Bayer AG - Vendor overview
  • Exhibit 61: Bayer AG - Business segments
  • Exhibit 62: Bayer AG - Organizational developments
  • Exhibit 63: Bayer AG - Geographic focus
  • Exhibit 64: Bayer AG - Segment focus
  • Exhibit 65: Bayer AG - Key offerings
  • Exhibit 66: Bayer AG - Key customers
  • Exhibit 67: CSL Ltd. - Vendor overview
  • Exhibit 68: CSL Ltd. - Business segments
  • Exhibit 69: CSL Ltd. - Organizational developments
  • Exhibit 70: CSL Ltd. - Geographic focus
  • Exhibit 71: CSL Ltd. - Segment focus
  • Exhibit 72: CSL Ltd. - Key offerings
  • Exhibit 73: CSL Ltd. - Key customers
  • Exhibit 74: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 75: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 76: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 77: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 78: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 79: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 80: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 81: Grifols SA - Vendor overview
  • Exhibit 82: Grifols SA - Business segments
  • Exhibit 83: Grifols SA - Organizational developments
  • Exhibit 84: Grifols SA - Geographic focus
  • Exhibit 85: Grifols SA - Segment focus
  • Exhibit 86: Grifols SA - Key offerings
  • Exhibit 87: Grifols SA - Key customers
  • Exhibit 88: Novo Nordisk AS - Vendor overview
  • Exhibit 89: Novo Nordisk AS - Business segments
  • Exhibit 90: Novo Nordisk AS - Organizational developments
  • Exhibit 91: Novo Nordisk AS - Geographic focus
  • Exhibit 92: Novo Nordisk AS - Segment focus
  • Exhibit 93: Novo Nordisk AS - Key offerings
  • Exhibit 94: Novo Nordisk AS - Key customers
  • Exhibit 95: Octapharma AG - Vendor overview
  • Exhibit 96: Octapharma AG - Organizational developments
  • Exhibit 97: Octapharma AG - Key offerings
  • Exhibit 98: Octapharma AG - Key customers
  • Exhibit 99: Pfizer Inc. - Vendor overview
  • Exhibit 100: Pfizer Inc. - Business segments
  • Exhibit 101: Pfizer Inc. - Organizational developments
  • Exhibit 102: Pfizer Inc. - Geographic focus
  • Exhibit 103: Pfizer Inc. - Segment focus
  • Exhibit 104: Pfizer Inc. - Key offerings
  • Exhibit 105: Pfizer Inc. - Key customers
  • Exhibit 106: Sanofi - Vendor overview
  • Exhibit 107: Sanofi - Business segments
  • Exhibit 108: Sanofi - Organizational developments
  • Exhibit 109: Sanofi - Geographic focus
  • Exhibit 110: Sanofi - Segment focus
  • Exhibit 111: Sanofi - Key offerings
  • Exhibit 112: Sanofi - Key customers
  • Exhibit 113: Takeda Pharmaceutical Co. Ltd. - Vendor overview
  • Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Business segments
  • Exhibit 115: Takeda Pharmaceutical Co. Ltd. - Organizational developments
  • Exhibit 116: Takeda Pharmaceutical Co. Ltd. - Geographic focus
  • Exhibit 117: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • Exhibit 118: Takeda Pharmaceutical Co. Ltd. - Key customers
  • Exhibit 119: Validation techniques employed for market sizing
  • Exhibit 120: Definition of market positioning of vendors
Back to Top